| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causin NCT06745024 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients NCT05924672 | University of California, San Francisco | Phase 2 |
| Recruiting | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases NCT06549478 | City of Hope Medical Center | Phase 1 |
| Withdrawn | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors NCT05010096 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Prog NCT04928820 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant NCT04489719 | University of Washington | — |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication NCT04071236 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel NCT04090398 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Active Not Recruiting | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer NCT03796767 | University of Utah | Phase 2 |
| Active Not Recruiting | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients NCT03793166 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma NCT03858205 | University of Southern California | N/A |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Completed | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Canc NCT03749460 | University of Washington | Phase 1 / Phase 2 |
| Completed | 18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radio NCT05174026 | M.D. Anderson Cancer Center | N/A |
| Completed | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast C NCT03012230 | Mayo Clinic | Phase 1 |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis NCT02699697 | Wake Forest University Health Sciences | N/A |
| Terminated | Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeleta NCT02715856 | M.D. Anderson Cancer Center | N/A |
| Terminated | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cance NCT02565901 | University of Washington | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Terminated | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistan NCT02429804 | Stanford University | Phase 1 |
| Completed | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival NCT02364557 | NRG Oncology | Phase 2 / Phase 3 |
| Active Not Recruiting | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing NCT02306161 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide NCT02099864 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel- NCT01833208 | Roswell Park Cancer Institute | N/A |
| Completed | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients Wit NCT00936975 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate o NCT01050504 | University of Washington | — |